AbbVie ROE 2010-2023 | ABBV
Current and historical return on equity (ROE) values for AbbVie (ABBV) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.
| AbbVie ROE - Return on Equity Historical Data |
| Date |
TTM Net Income |
Shareholder's Equity |
Return on Equity |
| 2023-12-31 |
$4.86B |
$10.40B |
39.92% |
| 2023-09-30 |
$6.51B |
$12.13B |
46.85% |
| 2023-06-30 |
$8.69B |
$12.90B |
58.37% |
| 2023-03-31 |
$7.59B |
$13.30B |
49.49% |
| 2022-12-31 |
$11.84B |
$17.29B |
73.61% |
| 2022-09-30 |
$13.41B |
$16.03B |
85.85% |
| 2022-06-30 |
$12.64B |
$14.69B |
84.23% |
| 2022-03-31 |
$12.48B |
$16.31B |
86.18% |
| 2021-12-31 |
$11.54B |
$15.44B |
83.43% |
| 2021-09-30 |
$7.53B |
$13.58B |
56.86% |
| 2021-06-30 |
$6.66B |
$12.59B |
48.71% |
| 2021-03-31 |
$5.16B |
$13.73B |
36.30% |
| 2020-12-31 |
$4.62B |
$13.10B |
51.72% |
| 2020-09-30 |
$7.38B |
$15.29B |
204.54% |
| 2020-06-30 |
$6.96B |
$14.73B |
-306.44% |
| 2020-03-31 |
$8.44B |
$-7.42B |
-104.22% |
| 2019-12-31 |
$7.88B |
$-8.17B |
-96.15% |
| 2019-09-30 |
$3.26B |
$-8.23B |
-39.38% |
| 2019-06-30 |
$4.12B |
$-8.57B |
-59.34% |
| 2019-03-31 |
$5.36B |
$-7.83B |
-95.00% |
| 2018-12-31 |
$5.69B |
$-8.45B |
-203.31% |
| 2018-09-30 |
$7.57B |
$-2.92B |
1285.47% |
| 2018-06-30 |
$6.45B |
$-3.38B |
215.65% |
| 2018-03-31 |
$6.38B |
$3.55B |
119.57% |
| 2017-12-31 |
$5.31B |
$5.10B |
93.18% |
| 2017-09-30 |
$6.65B |
$6.69B |
119.09% |
| 2017-06-30 |
$6.62B |
$6.01B |
119.66% |
| 2017-03-31 |
$6.31B |
$5.00B |
116.08% |
| 2016-12-31 |
$5.95B |
$4.64B |
111.33% |
| 2016-09-30 |
$6.08B |
$6.47B |
117.49% |
| 2016-06-30 |
$5.72B |
$5.64B |
119.85% |
| 2016-03-31 |
$5.48B |
$4.64B |
115.56% |
| 2015-12-31 |
$5.14B |
$3.95B |
131.15% |
| 2015-09-30 |
$2.82B |
$4.86B |
83.55% |
| 2015-06-30 |
$2.08B |
$5.50B |
62.83% |
| 2015-03-31 |
$1.82B |
$1.38B |
55.95% |
| 2014-12-31 |
$1.77B |
$1.74B |
43.53% |
| 2014-09-30 |
$3.71B |
$4.65B |
77.93% |
| 2014-06-30 |
$4.17B |
$5.22B |
92.75% |
| 2014-03-31 |
$4.14B |
$4.70B |
101.45% |
| 2013-12-31 |
$4.13B |
$4.49B |
113.22% |
| 2013-09-30 |
$4.54B |
$3.58B |
134.97% |
| 2013-06-30 |
$5.16B |
$3.56B |
80.81% |
| 2013-03-31 |
$5.36B |
$2.96B |
64.01% |
| 2012-12-31 |
$5.28B |
$3.36B |
49.54% |
| 2012-09-30 |
$4.89B |
$15.67B |
38.25% |
| 2012-06-30 |
$3.32B |
$11.51B |
37.42% |
| 2012-03-31 |
$3.59B |
$12.05B |
59.93% |
| 2011-12-31 |
$3.43B |
$11.93B |
115.09% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$296.212B |
$54.318B |
|
AbbVie has become one of the top-most pharma companies after it acquired Allergan. The deal has transformed AbbVie's portfolio by lowering its dependence on Humira, its flagship product. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest immunology drugs Skyrizi and Rinvoq position it well for long-term growth. AbbVie came into existence after Abbott Laboratories divested its pharmaceutical division. AbbVie enjoys leadership positions in key therapeutic areas including immunology, hematologic oncology, neuroscience, aesthetics, eye care and womens' health. Humira is approved for several autoimmune diseases like rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis, Crohn's disease and others. Imbruvica became part of the company's portfolio following the Pharmacyclics acquisition. Other key drugs include Venclexta, Botox Cosmetic, Botox Therapeutics, Vraylar, Skyrizi and Rinvoq.
|
